505 related articles for article (PubMed ID: 33606901)
1. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study.
Boughton CK; Hartnell S; Thabit H; Poettler T; Herzig D; Wilinska ME; Ashcroft NL; Sibayan J; Cohen N; Calhoun P; Bally L; Mader JK; Evans M; Leelarathna L; Hovorka R
Diabetes Obes Metab; 2021 Jun; 23(6):1389-1396. PubMed ID: 33606901
[TBL] [Abstract][Full Text] [Related]
2. Hybrid Closed-Loop with Faster Insulin Aspart Compared with Standard Insulin Aspart in Very Young Children with Type 1 Diabetes: A Double-Blind, Multicenter, Randomized, Crossover Study.
Ware J; Allen JM; Boughton CK; Cezar A; Hartnell S; Wilinska ME; Thankamony A; Deakin M; Leyland H; Phelan K; Thornborough K; Hovorka R
Diabetes Technol Ther; 2023 Jun; 25(6):431-436. PubMed ID: 36880866
[TBL] [Abstract][Full Text] [Related]
3. CamAPS FX Hybrid Closed-Loop with Ultra-Rapid Lispro Compared with Standard Lispro in Adults with Type 1 Diabetes: A Double-Blind, Randomized, Crossover Study.
Nwokolo M; Lakshman R; Hartnell S; Alwan H; Ware J; Allen JM; Wilinska ME; Evans ML; Hovorka R; Boughton CK
Diabetes Technol Ther; 2023 Dec; 25(12):856-863. PubMed ID: 37823892
[No Abstract] [Full Text] [Related]
4. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
[TBL] [Abstract][Full Text] [Related]
5. Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Very Young Children: A Multicenter, 3-Week, Randomized Trial.
Tauschmann M; Allen JM; Nagl K; Fritsch M; Yong J; Metcalfe E; Schaeffer D; Fichelle M; Schierloh U; Thiele AG; Abt D; Kojzar H; Mader JK; Slegtenhorst S; Barber N; Wilinska ME; Boughton C; Musolino G; Sibayan J; Cohen N; Kollman C; Hofer SE; Fröhlich-Reiterer E; Kapellen TM; Acerini CL; de Beaufort C; Campbell F; Rami-Merhar B; Hovorka R;
Diabetes Care; 2019 Apr; 42(4):594-600. PubMed ID: 30692242
[TBL] [Abstract][Full Text] [Related]
6. Fully Closed-Loop Glucose Control Compared With Insulin Pump Therapy With Continuous Glucose Monitoring in Adults With Type 1 Diabetes and Suboptimal Glycemic Control: A Single-Center, Randomized, Crossover Study.
Boughton CK; Hartnell S; Lakshman R; Nwokolo M; Wilinska ME; Ware J; Allen JM; Evans ML; Hovorka R
Diabetes Care; 2023 Nov; 46(11):1916-1922. PubMed ID: 37616583
[TBL] [Abstract][Full Text] [Related]
7. Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study.
Boughton CK; Hartnell S; Thabit H; Mubita WM; Draxlbauer K; Poettler T; Wilinska ME; Hood KK; Mader JK; Narendran P; Leelarathna L; Evans ML; Hovorka R
Lancet Healthy Longev; 2022 Mar; 3(3):e135-e142. PubMed ID: 35359882
[TBL] [Abstract][Full Text] [Related]
8. Short-term fully closed-loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes.
Bally L; Herzig D; Ruan Y; Wilinska ME; Semmo M; Vogt A; Wertli MM; Vogt B; Stettler C; Hovorka R
Diabetes Obes Metab; 2019 Dec; 21(12):2718-2722. PubMed ID: 31464063
[TBL] [Abstract][Full Text] [Related]
9. Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial.
Dovc K; Piona C; Yeşiltepe Mutlu G; Bratina N; Jenko Bizjan B; Lepej D; Nimri R; Atlas E; Muller I; Kordonouri O; Biester T; Danne T; Phillip M; Battelino T
Diabetes Care; 2020 Jan; 43(1):29-36. PubMed ID: 31575640
[TBL] [Abstract][Full Text] [Related]
10. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.
Bally L; Thabit H; Kojzar H; Mader JK; Qerimi-Hyseni J; Hartnell S; Tauschmann M; Allen JM; Wilinska ME; Pieber TR; Evans ML; Hovorka R
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):261-270. PubMed ID: 28094136
[TBL] [Abstract][Full Text] [Related]
11. Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial.
Ware J; Boughton CK; Allen JM; Wilinska ME; Tauschmann M; Denvir L; Thankamony A; Campbell FM; Wadwa RP; Buckingham BA; Davis N; DiMeglio LA; Mauras N; Besser REJ; Ghatak A; Weinzimer SA; Hood KK; Fox DS; Kanapka L; Kollman C; Sibayan J; Beck RW; Hovorka R;
Lancet Digit Health; 2022 Apr; 4(4):e245-e255. PubMed ID: 35272971
[TBL] [Abstract][Full Text] [Related]
12. Comparable Glucose Control with Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System During Exercise.
Morrison D; Zaharieva DP; Lee MH; Paldus B; Vogrin S; Grosman B; Roy A; Kurtz N; O'Neal DN
Diabetes Technol Ther; 2022 Feb; 24(2):93-101. PubMed ID: 34524022
[No Abstract] [Full Text] [Related]
13. A Comparison of Faster Insulin Aspart with Standard Insulin Aspart Using Hybrid Automated Insulin Delivery System in Active Children and Adolescents with Type 1 Diabetes: A Randomized Double-Blind Crossover Trial.
Dovc K; Bergford S; Fröhlich-Reiterer E; Zaharieva DP; Potocnik N; Müller A; Lenarcic Z; Calhoun P; Fritsch M; Sourij H; Bratina N; Kollman C; Battelino T
Diabetes Technol Ther; 2023 Sep; 25(9):612-621. PubMed ID: 37404205
[No Abstract] [Full Text] [Related]
14. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
Klonoff DC; Evans ML; Lane W; Kempe HP; Renard E; DeVries JH; Graungaard T; Hyseni A; Gondolf T; Battelino T
Diabetes Obes Metab; 2019 Apr; 21(4):961-967. PubMed ID: 30537180
[TBL] [Abstract][Full Text] [Related]
15. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
[TBL] [Abstract][Full Text] [Related]
16. Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study.
Ozer K; Cooper AM; Ahn LP; Waggonner CR; Blevins TC
Diabetes Technol Ther; 2021 Apr; 23(4):286-292. PubMed ID: 33090016
[TBL] [Abstract][Full Text] [Related]
17. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
Tauschmann M; Thabit H; Bally L; Allen JM; Hartnell S; Wilinska ME; Ruan Y; Sibayan J; Kollman C; Cheng P; Beck RW; Acerini CL; Evans ML; Dunger DB; Elleri D; Campbell F; Bergenstal RM; Criego A; Shah VN; Leelarathna L; Hovorka R;
Lancet; 2018 Oct; 392(10155):1321-1329. PubMed ID: 30292578
[TBL] [Abstract][Full Text] [Related]
18. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
19. Fast-Acting Insulin Aspart Use with the MiniMed
Hsu L; Buckingham B; Basina M; Ekhlaspour L; von Eyben R; Wang J; Lal RA
Diabetes Technol Ther; 2021 Jan; 23(1):1-7. PubMed ID: 32520594
[No Abstract] [Full Text] [Related]
20. Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial.
Daly AB; Boughton CK; Nwokolo M; Hartnell S; Wilinska ME; Cezar A; Evans ML; Hovorka R
Nat Med; 2023 Jan; 29(1):203-208. PubMed ID: 36631592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]